| 1 |
25096913 | Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells. | 2014 Dec |
5 |
| 2 |
23524664 | Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. | 2013 Jun |
1 |
| 3 |
12015757 | A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. | 2002 May 1 |
3 |
| 4 |
9815696 | A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile. | 1997 Mar |
3 |
| 5 |
7544429 | Cytotoxic chemotherapy for adrenocortical carcinoma. | 1995 Mar |
4 |
| 6 |
8098948 | Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. | 1993 |
1 |
| 7 |
1675220 | Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. | 1991 Jul |
10 |